2395.T Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 02:15):

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally...

Stats
Today's Volume	147 900
Average Volume	354 803
Market Cap	61.62B
EPS	¥0 ( 2024-02-01 )
Next earnings date	( ¥12.99 ) 2024-05-08
Last Dividend	¥30.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	11.19
ATR14	¥0.790 (0.05%)

Volume Correlation

Long: -0.04 (neutral)

Short: -0.24 (neutral)

Signal:(41.153) Neutral

Shin Nippon Biomedical Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Shin Nippon Biomedical Correlation - Currency/Commodity

0.02
( neutral )

0.04
( neutral )

-0.24
( neutral )

0.36
( neutral )

0.33
( neutral )

-0.07
( neutral )

Shin Nippon Biomedical Financials

Annual	2022
Revenue:	¥25.09B
Gross Profit:	¥13.05B (52.00 %)
EPS:	¥145.57

Q3	2023
Revenue:	¥6.10B
Gross Profit:	¥3.18B (52.19 %)
EPS:	¥19.90

Q2	2023
Revenue:	¥6.08B
Gross Profit:	¥3.16B (51.97 %)
EPS:	¥38.26

Q1	2023
Revenue:	¥5.80B
Gross Profit:	¥3.19B (55.02 %)
EPS:	¥32.99

Financial Reports:

No articles found.

Shin Nippon Biomedical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥20.00 (N/A)	¥0 (N/A)	¥30.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Shin Nippon Biomedical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.22 - Stable (4.41%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥0.500	2004-03-26
Last Dividend	¥30.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	15	--
Total Paid Out	¥99.00	--
Avg. Dividend % Per Year	0.00%	--
Score	2.72	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.22
Div. Directional Score	7.89	--

Next Divdend (Est)
(2024-07-08)

¥0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

2.72

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8137.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7487.T	Ex Dividend Junior	2024-05-30	Annually	0.00%
6715.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
6059.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
4739.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3983.T	Ex Dividend Knight	2023-12-28	Annually	0.00%
3193.T	Ex Dividend Junior	2024-01-30	Annually	0.00%
2183.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
9055.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7943.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.206	1.500	5.88	8.82	[0 - 0.5]
returnOnAssetsTTM	0.0771	1.200	7.43	8.92	[0 - 0.3]
returnOnEquityTTM	0.192	1.500	8.98	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.496	0.800	7.52	6.02	[1 - 3]
quickRatioTTM	0.835	0.800	9.80	7.84	[0.8 - 2.5]
cashRatioTTM	0.571	1.500	7.94	10.00	[0.2 - 2]
debtRatioTTM	0.374	-1.500	3.77	-5.65	[0 - 0.6]
interestCoverageTTM	30.41	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	85.79	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	85.79	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.884	-1.500	6.46	-9.69	[0 - 2.5]
grossProfitMarginTTM	0.522	1.000	4.63	4.63	[0.2 - 0.8]
operatingProfitMarginTTM	0.150	1.000	9.01	9.01	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.134	1.000	-0.368	-0.368	[0.2 - 2]
assetTurnoverTTM	0.374	0.800	-0.839	-0.671	[0.5 - 2]
Total Score				10.55

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	11.23	1.000	8.97	0	[1 - 100]
returnOnEquityTTM	0.192	2.50	9.34	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	85.79	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	3.37	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	85.79	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.0918	1.500	-3.95	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.134	1.000	9.16	0	[0.1 - 0.5]
Total Score				5.22

Shin Nippon Biomedical

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.